Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RLYB116 in Healthy Participants
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs RLYB 116 (Primary)
- Indications Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions
- Sponsors Rallybio
- 03 Feb 2025 New trial record